US equities |
SPCX $166.97 ▲+5.04% NVDA $236.81 ▲+1.22% MU $1,063.19 ▼-1.09% TSLA $377.45 ▲+1.85% MSFT $526.47 ▲+1.73% SNDK $1,709.00 ▼-0.64% INTC $117.36 ▼-1.65% META $744.62 ▲+2.27%
FinancialContent

Articles published by ACELYRIN, INC.

News headline image
ACELYRIN Stockholders Approve Merger with Alumis to Create Clinical Biopharma Company Dedicated to Innovating, Developing and Commercializing Transformative Therapies for Immune-mediated Diseases
From ACELYRIN, INC.
Via GlobeNewswire
Tickers ALMS SLRN
News headline image
Leading Independent Proxy Advisory Firm ISS Recommends ACELYRIN Stockholders Vote “FOR” the Proposed Transaction with Alumis
From ACELYRIN, INC.
Via GlobeNewswire
Tickers ALMS SLRN
News headline image
ACELYRIN Reiterates Benefits of Value-Maximizing Combination with Alumis
From ACELYRIN, INC.
Via GlobeNewswire
Tickers ALMS SLRN
News headline image
Alumis and ACELYRIN Announce Amended Merger Agreement
From ACELYRIN, INC.
Via GlobeNewswire
Tickers ALMS SLRN
News headline image
ACELYRIN Adopts Limited-Duration Stockholder Rights Plan
From ACELYRIN, INC.
Via GlobeNewswire
Tickers SLRN
News headline image
ACELYRIN and Alumis Reaffirm Strategic and Financial Rationale of Proposed Merger
From ACELYRIN, INC.
Via GlobeNewswire
Tickers ALMS SLRN
News headline image
ACELYRIN Determines Unsolicited Indication of Interest From Concentra Biosciences Not Reasonably Expected to Result in a Superior Proposal to Planned Alumis Merger
From ACELYRIN, INC.
Via GlobeNewswire
Tickers ALMS SLRN
News headline image
ACELYRIN Confirms Receipt of Unsolicited Indication of Interest from Concentra Biosciences
From ACELYRIN, INC.
Via GlobeNewswire
Tickers ALMS SLRN
News headline image
Alumis and ACELYRIN to Merge Creating a Late-Stage Clinical Biopharma Company Dedicated to Innovating, Developing and Commercializing Transformative Therapies for Immune-mediated Diseases
From ACELYRIN, INC.
Via GlobeNewswire
Tickers ALMS SLRN
News headline image
ACELYRIN, INC. Announces Additional Phase 2 Data and Phase 3 Program Design for Lonigutamab in Thyroid Eye Disease
From ACELYRIN, INC.
Via GlobeNewswire
Tickers SLRN
News headline image
ACELYRIN, INC. to Host Virtual Investor Event to Share new Phase 2 Data and Phase 3 Program Design for Subcutaneous Lonigutamab
From ACELYRIN, INC.
Via GlobeNewswire
Tickers SLRN
News headline image
ACELYRIN, INC. Announces Topline Results From Phase 2b/3 Study of Izokibep for the Treatment of Uveitis
From ACELYRIN, INC.
Via GlobeNewswire
Tickers SLRN
News headline image
ACELYRIN, INC. Reports Third Quarter 2024 Financial Results and Recent Highlights
From ACELYRIN, INC.
Via GlobeNewswire
Tickers SLRN
News headline image
ACELYRIN, INC. to Report Third Quarter 2024 Financial Results and Corporate Update on November 13, 2024
From ACELYRIN, INC.
Via GlobeNewswire
Tickers SLRN
News headline image
ACELYRIN, INC. Forms Scientific and Patient Advisory Board Featuring Leading Voices in Thyroid Eye Disease
From ACELYRIN, INC.
Via GlobeNewswire
Tickers SLRN
News headline image
ACELYRIN, INC. Announces Positive Results from Global Phase 3 Clinical Trial of Izokibep in Hidradenitis Suppurativa to be Highlighted in Late-Breaking Oral Presentation at EADV 2024
From ACELYRIN, INC.
Via GlobeNewswire
Tickers SLRN
News headline image
ACELYRIN, INC. Announces Positive Proof-of-Concept Data From Phase 1/2 Clinical Trial of Lonigutamab as a Subcutaneous Treatment for Thyroid Eye Disease to be Presented at 42nd Annual Meeting of European Society of Ophthalmic Plastic and Reconstructive
From ACELYRIN, INC.
Via GlobeNewswire
Tickers SLRN
News headline image
ACELYRIN, INC. to Participate in Upcoming Investor Conferences
From ACELYRIN, INC.
Via GlobeNewswire
Tickers SLRN
News headline image
ACELYRIN, INC. Announces Positive Phase 3 Data for Izokibep in Hidradenitis Suppurativa; Focuses Strategy on Lonigutamab and Reports Second Quarter 2024 Financial Results
From ACELYRIN, INC.
Via GlobeNewswire
Tickers SLRN
News headline image
ACELYRIN, INC. to Report Second Quarter 2024 Financial Results and Corporate Update on August 13, 2024
From ACELYRIN, INC.
Via GlobeNewswire
Tickers SLRN
News headline image
ACELYRIN, INC. Announces Positive 16-week Data From its Global Phase 2b/3 Trial of Izokibep in Psoriatic Arthritis to be Shared During Late-Breaking Oral Presentation at EULAR 2024
From ACELYRIN, INC.
Via GlobeNewswire
Tickers SLRN
News headline image
ACELYRIN, INC. Announces Lonigutamab Phase 1/2 Proof-Of-Concept Data to be Shared During Late-Breaking Oral Presentation at ENDO 2024
From ACELYRIN, INC.
Via GlobeNewswire
Tickers SLRN
News headline image
ACELYRIN, INC. Provides Business Update and Highlights Key Upcoming Milestones
From ACELYRIN, INC.
Via GlobeNewswire
Tickers SLRN
News headline image
ACELYRIN, INC. Announces Leadership Transition
From ACELYRIN, INC.
Via GlobeNewswire
Tickers SLRN
News headline image
ACELYRIN, INC. to Report First Quarter 2024 Financial Results and Corporate Update on May 13, 2024
From ACELYRIN, INC.
Via GlobeNewswire
Tickers SLRN
News headline image
ACELYRIN, INC. Reports Full Year 2023 Financial Results and Recent Highlights
From ACELYRIN, INC.
Via GlobeNewswire
Tickers SLRN
News headline image
ACELYRIN, INC. Announces Positive Phase 1/2 Proof-of-Concept Data for Lonigutamab, First Subcutaneous Anti-IGF-1R to Demonstrate Clinical Responses in Thyroid Eye Disease
From ACELYRIN, INC.
Via GlobeNewswire
Tickers SLRN
News headline image
ACELYRIN, INC. Announces Positive Top-line Results from Its Global Phase 2b/3 Clinical Trial of Izokibep in Psoriatic Arthritis
From ACELYRIN, INC.
Via GlobeNewswire
Tickers SLRN
News headline image
ACELYRIN, INC. Announces Long-term 32-Week Data from the Phase 2b Trial of Izokibep in Hidradenitis Suppurativa Demonstrating Sustained Responses and Deepening Clinical Benefit - Improving Quality of Life for Patients
From ACELYRIN, INC.
Via GlobeNewswire
Tickers SLRN
News headline image
ACELYRIN, INC. Appoints Agnes Lee as Senior Vice President, Investor Relations and Corporate Communications
From ACELYRIN, INC.
Via GlobeNewswire
Tickers SLRN